Guang Dong Wan Tai Ke Chuang Yao Ye You Xian Gong Si

Main study objectives To study the pharmacokinetics of the test preparation cefdinir dry suspension (specification: 250mg/5ml, provided by Guangdong Wantai Kechuang Pharmaceutical Co., Ltd.) and the reference preparation cefdinir dry suspension (specification: 250mg/5ml, licensee: Aurobindo Pharma Limited) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after fasting and fed oral administration. Secondary study objectives To evaluate the safety of the test preparation cefdinir dry suspension and the reference preparation cefdinir dry suspension after a single oral administration in the fasting and fed state in healthy Chinese subjects.

Main study objectives To study the pharmacokinetics of the test preparation levamlodipine besylate tablets (specification: 5mg, provided by Guangdong Wantai Kechuang Pharmaceutical Co., Ltd.) and the reference preparation amlodipine besylate tablets (Norvasc®; specification: 10mg; licensee: Pfizer Pharmaceuticals Co., Ltd.) in healthy adult subjects in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary study objectives To evaluate the safety of the test preparation levamlodipine besylate tablets and the reference preparation amlodipine besylate tablets (Norvasc®) in healthy Chinese subjects in the fasting and fed state after a single oral administration.

Main research purpose Study the single oral administration of the test preparation pitavastatin calcium orally disintegrating tablets (specification: 4 mg, provided by Guangdong Wantai Kechuang Pharmaceutical Co., Ltd.) and the reference preparation pitavastatin calcium orally disintegrating tablets (Livalo OD) in the fasting and postprandial states. , Specification: 4mg, Licensee: Kowa Co., Ltd.), pharmacokinetics in healthy adult subjects, and evaluate the bioequivalence of the two preparations taken orally on an empty stomach and after a meal. Secondary research purpose To evaluate the safety of Chinese healthy subjects after a single oral administration of the test preparation pitavastatin calcium orally disintegrating tablets and the reference preparation pitavastatin calcium orally disintegrating tablets (Livalo OD) in fasting and postprandial states.